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Abstract 
A proportion of human immunodeficiency virus (HIV)–infected patients develop 
persistent, stigmatizing human papillomavirus (HPV)–related cutaneous and 
genital warts and anogenital (pre)cancer. This is the first study to investigate 
immunogenetic variations that might account for HPV susceptibility and the 
largest to date to categorize the HPV types associated with cutaneous warts in 
HIV-positive patients. The HLA class I and II allele distribution was analyzed in 
49 antiretroviral (ART)–treated HIV-positive patients with persistent warts, 42 
noninfected controls, and 46 HIV-positive controls. The allele HLA-B*44 was 
more frequently identified in HIV-positive patients with warts (P = .004); a 
susceptible haplotype (HLA-B*44, HLA-C*05; P = .001) and protective genes 
(HLA-DQB1*06; P = .03) may also contribute. Cutaneous wart biopsy specimens 
from HIV-positive patients harbored common wart types HPV27/57, the unusual 
wart type HPV7, and an excess of Betapapillomavirus types (P = .002), compared 
with wart specimens from noninfected controls. These findings suggest that HLA 
testing might assist in stratifying those patients in whom vaccination should be 
recommended.  
 
Introduction 
Human immunodeficiency virus (HIV)–infected individuals are commonly 
afflicted with troublesome cutaneous and genital warts and genital precancer and 
cancer despite receipt of fully suppressive antiretroviral therapy (ART). The virus 
that causes warts, human papillomavirus (HPV), is classified on the basis of its 
DNA sequence into 5 genera, containing >120 different genotypes: 
Alphapapillomavirus (predominantly comprising genital HPV types but also 
including cutaneous wart types), Mupapillomavirus, Nupapillomavirus, 
Gammapapillomavirus (containing cutaneous wart types), and Betapapillomavirus 
(largely nonpathogenic cutaneous types) [1, 2]. HPV is ubiquitous; HPV types 
belonging to the Betapapillomavirus genus are detected with a high prevalence 
(>95%) in the general population, and it is estimated that around 75% of all 
individuals have been exposed to genital HPV types, mostly subclinically and 
without morbidity [3, 4]. HPV-related disease in HIV-infected patients is common 
and frequently results in a disabling and stigmatizing dermatosis, consuming 
significant clinical resources. HIV infection probably increases the prevalence of 
warts and other HPV-related diseases, and these diseases do not appear to abate 
with fully suppressive ART [5–8]. Persistent HPV genital disease in HIV-infected 
patients can lead to the development of precancerous lesions with the risk of 
progression to frank cancer. However, many individuals remain disease-free 
despite presumed HPV exposure, whereas others are particularly troubled by 
HPV-associated diseases. This transition is likely to be augmented by long-
standing HIV infection [9, 10]. The pattern and severity of skin disease in HIV-
infected patients may be determined by factors that transcend their level of 
immunodysfunction, such as immunogenotype, of which CD4+ T-cell count is just 
one marker. We investigated the immunogenotype (specifically, the HLA type) of 
HIV-infected patients with persistent viral warts and identified the HPV types in 
HIV-positive individuals with cutaneous and genital warts.  
Methods 
Subjects  
Ethics approval was sought and received from the Riverside NHS Research Ethics 
Committee (London, United Kingdom) before study commencement. Informed 
written consent was taken from all patients. Participants were white Caucasoid (ie, 
they reported parental and grandparental ancestry from Northern Europe, defined 
as the United Kingdom, Ireland, Netherlands, Belgium, France, Germany, 
Switzerland, and the Scandinavian countries). In brief, 3 patient groups were 
recruited: (1) HIV-positive cases, defined as HIV-positive individuals with HPV 
disease and a history of persistent (duration, ≥6 months) cutaneous/genital warts 
(with or without a history of HPV related anogenital precancer); (2) HIV-positive 
controls, defined as HIV-positive patients without a history of persistent HPV 
disease; and (3) HIV-negative cases, defined as individuals without HIV infection 
and with HPV disease (as defined above).  
All HIV-positive individuals were male, were infected with HIV-1 and had been 
taking fully suppressive ART for ≥1 year (HIV load <50 copies/mL for ≥6 
months). HIV-positive controls had an absent or transitory past history (<3 
months) of warts and no evidence of other HPV-related diseases, based on their 
medical history, case note review, and dermatological examination findings. 
Females with cutaneous warts (with or without genital warts) were included in the 
HIV-negative case group, but females with a history of genital warts or cervical 
abnormalities alone were not. HIV-negative cases were individuals with persistent 
warts in good physical health with no clinical indicators and no other risk factors 
for HIV infection (as assessed by private interview and thorough dermatological 
examination) and/or a negative result of an HIV antibody test. To be included as 
HIV-negative cases, men who have sex with men (MSM) either had a recent 
negative result of an HIV test or consented to HIV antibody testing (all test results 
were negative for HIV antibody). From a cohort of approximately 5000 HIV-
infected patients attending the HIV clinic at Chelsea and Westminster Hospital 
(London) and from other clinics in the same hospital, 137 Caucasoid individuals 
were recruited (49 HIV-positive cases, 42 HIV-negative cases, and 46 HIV-
positive controls). These individuals were HLA typed. A subset of HLA-typed 
patients with warts at the time of review provided fresh wart tissue for HPV 
typing, resulting in 106 wart specimens from 30 HIV-positive cases and 36 HIV-
negative cases. Demographic information was collected for all patients and 
included ethnicity, age, sex, total wart duration for cases (volunteered by the 
patient and corroborated by patient case records), year of HIV infection diagnosis 
and ART commencement, nadir CD4+ T-cell count (corroborated by the year of 
ART initiation and defined as the lowest historical recorded CD4+ T-cell count).  
HLA Typing  
DNA was extracted from fresh frozen whole-blood specimens, using standard 
Qiagen protocols (Qiagen, Crawley, United Kingdom) [11] and underwent HLA 
typing by a validated laboratory (Anthony Nolan Histocompatibility Laboratories, 
London), using a commercial Luminex-based platform (One Lambda LABtype 
SSO typing, VH Bio, Gateshead, United Kingdom). HLA allele frequencies for 
Caucasoid individuals derived from UK based populations were also available 
[12–14]. HLA-A, HLA-B, and HLA-DRB1 allele frequencies were taken from a 
population of 5024 Caucasoid blood donors who attended a UK blood transfusion 
centre; HLA-C frequencies were derived from a subgroup of 2420 individuals 
from the same population. HLA-DQB1 frequencies were from 177 individuals 
included in a London anthropology study comprising subjects from England, 
Scotland, Wales, and Northern Ireland; HLA-B*44 allele subtypes were obtained 
from 298 Caucasoid blood donors from Liverpool, United Kingdom.  
HPV Typing  
Study subjects with warts were offered surgical treatment (curettage/shave biopsy 
or excision). Wart biopsy specimens were divided: half were sent in 10% formalin 
for confirmatory histopathologic analysis, and the remaining fresh tissue 
specimens were snap frozen and used for DNA extraction; one of the 106 samples 
was derived from recently processed formalin-fixed paraffin-embedded tissue. 
Clinically diagnosed (by a dermatologist) viral warts that were located on sites not 
easily amenable to surgical biopsy under local anesthetic (eg, plantar, periungual, 
and finger warts) were pared deeply with a scalpel, and the parings were used for 
HPV typing. DNA was extracted from tissue by using standard Qiagen protocols 
as described above [11], with the addition of the following stringent anti-
contamination procedures: extended tissue lysis, a longer elution time, and a 
smaller elution volume. DNA from cutaneous wart associated HPV types was 
detected using 2 techniques: (1) nested PCR/sequencing designed to detect HPV 
types 3, 10, 28, 29, 77, 2, 27, 57, 1, 41, and 63, as well as other potentially novel 
types [15]; and (2) a newly developed Luminex-based platform (HSL-PCR/MPG), 
using broad-spectrum primers and probes to detect both the types specified above 
and the additional HPV types 7, 4, 40, 43, 48, 50, 60, 65, 88, 91, 94, and 95 [16]. 
Thus, 23 cutaneous wart associated HPV types were detectable. Genital and 
Betapapillomavirus types were distinguished using 2 separate commercial reverse 
hybridization line probe assays. The genital assay [17, 18] identified 25 HPV 
types: high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 
and 70 and low risk HPV types 6, 11, 34, 40, 42–44, 53, 54, and 74 (HPV SPF10-
DEIA-LiPA25 system, version 1 [based on licensed Innogenetics technology]; 
Labo Biomedical Products, Rijswijk, the Netherlands). The Betapapillomavirus 
assay [19] contained probes that detected 25 HPV types: HPV 5, 8, 9, 12, 14, 15, 
17, 19, 20, 21, 22, 23, 24, 25, 36, 37, 38, 47, 49, 75, 76, 80, 92, 93, and 96 
(Diassay B.V., Rijswijk, The Netherlands).  
Statistical Analysis  
Descriptive and analytical statistics for HPV data were computed with the use of 
the following standard software programs and with the advice of the Statistical 
Advisory Service and St Stephens Centre (Imperial College, London): Microsoft 
Excel; Statistical Package for the Social Sciences (SPSS), version 20; and Epi Info 
(Centers for Disease Control and Prevention; available at: 
http://www.cdc.gov/epiinfo/; accessed 20 January 2009). Nonparametric data were 
analyzed with the Mann– Whitney U test. Categorical data were analyzed with 
Yates’ corrected χ2 or Fisher exact tests (2-tailed). Advice regarding HLA allele 
counting and immunophenotypic analysis was provided by the Anthony Nolan 
Histocompatibility Laboratories. A substantial Bonferroni correction for multiple 
testing was applied to each HLA analysis, to account for all potential allele 
comparisons, and was accomplished by multiplying the calculated P value by 135 
(denoted “Pcorrected”).  
Results 
Patient Attributes  
Results of HLA typing of DNA from blood specimens were available for 49 HIV-
positive cases and 42 HIV-negative cases with persistent warts (Table 1). Of these, 
most (86% [42 of 49] and 69% [29 of 42], respectively) had a history of cutaneous 
warts; 39% (19 of 49) and 45% (19 of 42), respectively, had a history of genital 
warts, and 24% (12 of 49) and 14% (6 of 42), respectively, had a history of both. 
Three individuals among HIV-positive cases and 3 among HIV-negative cases 
also had a history of HPV-related penile or anal cancer in situ. The median 
duration of self-reported warts in this study was between 3 and 5 years for both 
HIV-positive cases and HIV-negative cases; this long duration is expected because 
individuals with persistent warts for six months were recruited. HIV-positive cases 
and HIV-positive controls included significantly more males (100%; P < .0001) 
and MSM (98%; P < .0001) than HIV-negative cases, a function of the 
demographic characteristics of HIV clinic attendees (largely male); among HIV-
negative cases, 29% (12 of 42) were female and 15% (6 of 42) were MSM. 
Females with cutaneous warts were also included as HIV-negative cases because 
cutaneous warts in males and females are probably comparable. There were no 
other significant differences between study subjects.  
Molecular HLA data were reported as a standard string consisting of 2 allele fields 
(as defined by the assay manufacturer). The first field was used to determine the 
allele distribution, by phenotypic allele counting. Therefore, a homozygous 
individual counted only once toward the allele total (Figures 1 and 2 and 
Supplementary Table 1).  
The main HLA allele of interest that emerged from this study was HLA-B*44 
allele: 47% of HIV-positive cases (23 of 49) with HPV disease had this allele, 
compared with 17% of HIV-positive controls (8 of 46; P = .004; Pcorrected = .54) 
and with 32% of the blood donor population (1608 of 5024; P = .04; Pcorrected = 
1.0; Figure 1). The HLA-B*44 allele count for HIV-negative cases was between 
that for HIV-positive cases and HIV-positive controls, at 33% (14 of 42). Further 
interpretation of the allele subgroups revealed that HLA-B*44:02 was the 
predominant HLA-B*44 subtype; it was present in 38% of HIV-positive cases (18 
of 47), 7% of HIV-positive controls (3 of 46; P = .0006; Pcorrected = .04), and 19% 
of individuals (57 of 298) from a comparative United Kingdom Caucasoid blood 
donor population (P = .006; Pcorrected = .43). Another allele, HLA-C*05 was also 
seen more frequently in HIV-positive cases (33% [16 of 49]), compared with HIV-
positive controls (9% [4 of 46]; P = .009; Pcorrected = .59). HLA-B*44 and HLA-
C*05 are in linkage disequilibrium and constitute a common Caucasoid haplotype. 
Thirty-seven percent of HIV-positive cases (18 of 49) had the haplotype HLA-
B*44, -C*05, compared with only 7% of HIV-positive controls (3 of 46; P = .001; 
Pcorrected = .07). The allele HLA-DQB1*06 may also be of possible of interest 
because it was detected more frequently in HIV-positive controls (which makes it 
potentially protective against HPV disease), compared with United Kingdom 
Caucasoid blood donors (61% [28 of 46] vs 42% [74 of 177]; P = .03; Pcorrected = 
.8). There was no significant difference between the allele frequency of HLA-
DQB1*06 among HIV-positive cases (43% [21 of 49]) and that among HIV-
positive controls (61% [28 of 46]; P = .12).  
There was no significant difference in the number of subjects from each study 
group who were homozygous for least 1 allele at HLA-A, -B, -C, -DRB1, and -
DRB1 loci: 41% of HIV-positive cases (20 of 49) were homozygotes, compared 
with 43% of HIV-positive controls (20 of 46) and 57% of HIV-negative cases (24 
of 42; P = .24).  
HPV  
The characteristics of individuals in the HIV-negative and HIV-positive case 
groups who contributed HPV typing data from wart tissue specimens were almost 
identical to those of individuals included in the HLA analysis. HPV typing was 
performed for 30 HIV-positive cases (using tissue specimens from 38 cutaneous 
warts and 10 genital warts) and 36 HIV-negative cases (using tissue specimens 
from 46 cutaneous warts and 12 genital warts). All 106 sampled warts were 
positive for at least 1 HPV type (Figures 3 and 4 and Supplementary Table 2). 
However, in specimens from 4% of cutaneous warts (3 of 84) and 5% of genital 
warts (1 of 22), no likely pathogenic HPV type was identified, although 
Betapapillomavirus types were detected at low levels.  
Mixed HPV infections were common. For the cutaneous wart associated HPV 
types and genital HPV types combined, two or more HPV types from either group 
were detected in 29% (31 of 106) of warts. For the ubiquitous Betapapillomavirus 
HPV types, the detection of multiple types was higher in HIV-positive cases than 
in HIV-negative cases (60% [29 of 48] vs 38% [22 of 58]; P = .03). The median 
number of Betapapillomavirus types was also greater in HIV-positive cases than in 
HIV-negative cases (3 [interquartile range {IQR}, 0.3–8] vs 1 [IQR, 0–2]; P = 
.002). HPV 27 and 57 were the most commonly identified HPV types in all 
cutaneous warts (from both HIV-positive and HIV-negative cases; Figure 3). HPV 
2 was more frequently detected in specimens of cutaneous warts from HIV-
negative cases than those from HIV-positive cases (30% [14 of 46] vs 3% [1 of 
38]; P = .002). HPV 7 was identified in specimens of 8% of cutaneous warts (4 of 
38) from HIV-positive cases and in 0% (0 of 46) from HIV-negative individuals 
(P = .04). The HPV 7–positive warts were located on the face and head. After 
correction for multiple warts from a single individual, this difference for HPV 7 
was not statistically significant, with detection in 3 of 27 HIV-positive cases and 0 
of 26 HIV-negative cases (P = .2). HPV 11 and HPV 6 were identified in genital 
wart specimens from both HIV-positive and HIV-negative cases, and there was no 
difference in the HPV type prevalence; the number of genital warts examined was 
small.  
Discussion 
To our knowledge, this work is the first to examine the immunogenotypic profile 
of HIV-infected individuals with warts. The HLA class I allele groups HLA-B*44 
(as the allele subtype HLA-B*44:02) and HLA-C*05 were more frequent in HIV-
positive cases with persistent warts than in HIV-positive controls. The class II 
allele HLA-DQB1*06 was found more often in HIV-positive controls than in 
HIV-positive cases, implying it might have a moderate, possibly protective effect. 
However, after a conservative Bonferroni correction (ie, multiplication of the P 
value by 135), none of these associations were statistically significant, except for 
that of HLA-B*44:02 (Pcorrected = .04).  
The differences in the allele distributions suggest an HLA class I predisposition to 
HPV disease in HIV-infected individuals. The potential mechanisms behind HLA 
associations with HPV disease in individuals with treated HIV infection might 
operate at several levels; 2 viral pathogens are involved.  
The best evidence to date for HPV diseases (ie, data on cervical cancer and 
recurrent respiratory papillomatosis) suggests that predominantly HLA class II 
alleles appear to govern the host response to HPV. HLA-DRB1*13:01/02 and -
DQB1*06:03 have been associated with protection against HPV diseases, whereas 
HLA-DQB1*06:02 has been identified with discordant associations ( protective, 
neutral, or deleterious) [20–22]. Other alleles, such as HLA-DRB1*03:01 and 
HLA-DQB1*03:01/02/03, and the haplotype HLA-DRB1*15:01, -DQB1*06:02 
have been found to confer susceptibility [21, 23, 24]. There are few reports 
describing class I associations in HPV. However, HLA-B*44 was previously 
correlated, in a small number of subjects, with increased progression of HPV 16–
related cervical dysplasia [21, 25]. More data are provided by 2 studies that 
examined HLA class II (but not HLA class I) in immunocompetent individuals 
with cutaneous warts. None, to our knowledge, have studied HIV-infected 
patients. HLA-DRB1*03 and HLA-DRB1*09 were found more frequently in 
Mexican individuals with cutaneous warts than in the general population, and 
HLA-DR6 (HLA-DRB1*13/14)  
was found to be protective [26]. A German study compared 71 otherwise healthy 
individuals with persistent cutaneous warts lasting >18 months that were positive 
for HPV 2, 27, and 57 to 92 controls [27]. A statistically significant increase was 
seen in HLA-DQB1*03:01 and HLA-DQA1*03 in cases, compared with controls, 
consistent with previous studies in cervical cancer; nonsignificant trends were also 
identified for alleles, including HLA-DQB1*06:03 (protective). The data from the 
investigation herein in HIV-infected individuals suggest that HLA-DQB1*06 (all 
alleles combined) might be protective against HPV. Others have suggested this 
same allele may be protective in other HPV-related diseases, such as cervical 
cancer/precancer and recurrent respiratory papillomatosis [21]. One HPV-
protective HLA class II allele may be insufficient to prevent HPV disease in HIV-
infected individuals, and other protective alleles and/or fewer predisposing alleles 
may be necessary, such as the haplotype HLA-B*44, -C*05 in the absence of -
DQB1 that was seen in some of our HIV-positive cases.  
HIV disease progression, on the other hand, is thought to be HLA class I related. 
Alleles protective for HIV may be able to generate an effective CD8+ T-cell 
response to highly conserved HIV p24 peptides, while deleterious alleles may 
direct an ineffective immune response [28, 29]. HLA-B*27 and -B*57 have 
historically been most consistently associated with delayed HIV progression, and 
HLA-B*35 has been associated with HIV disease that progresses more rapidly. 
Other work suggested that the HLA-Bw4 group of alleles (HLA-B*44 is one) may 
influence the function of natural killer receptors (KIRs) in HIV infection [30, 31]. 
However, alleles such as HLA-B*27:02, HLA-B*57 (rather than HLA-B*44) are 
preferential ligands for the KIRs KIR3DL1/KIRDS1, and therefore the effect of 
weaker ligands such as HLA-B*44 may be clinically insignificant. It is possible 
that the allele of interest, HLA-B*44:02, is not related to HPV disease and may be 
a marker of greater HIV disease progression that is not reflected in variables such 
as HIV infection duration or nadir CD4+ T-cell count. Additionally, class II HLA 
molecules might affect thymic T-cell education. The thymus may be of particular 
importance in HIV infection during ART receipt because of the recognized 
emergence of naive CD4+ T-cells during immune recovery; this ability declines 
with aging, as does HIV-related prognosis [32].  
This study is also the first to comprehensively categorise the HPV type profile of 
warts from HIV-infected patients. It supports the limited evidence to date (from 
case reports) that HPV 7 may be an important pathogen in HIV-infected patients 
[33–35] and that HPV types commonly associated with warts (such as HPV 27/57 
in cutaneous warts) were frequently detected in wart specimens from HIV-infected 
patients. The only other study that typed HPV from a substantial collection of 
warts from HIV-infected patients found HPV 7 in specimens from 4% of wart 
specimens (1 of 25) in HIV-infected individuals but not in 14 wart specimens from 
non–HIV-infected subjects [36]. In the general population, HPV 7 has been 
reported infrequently (in 0.5%–2% of individuals) and in unusual sites [16, 37–
43]. Immunodysfunction may be important; HPV 7 was found in 17% of 23 wart 
specimens from 12 organ transplant recipients but was absent in several other 
studies that typed HPV in wart specimens from immunosuppressed patients [15, 
44–47]. However, it is possible that rarer HPV types (such as HPV 7) may be 
overrepresented in our HIV-infected cohort owing to propagation of the infection 
between individuals in close contact within the cohort (ie, the cohort is 
epidemiologically closed). MSM may potentially carry more HPV types, 
particularly genital types, through greater exposure to HPV. HPV 1 has been 
reported to be a common HPV type in cutaneous warts [38] but was absent from 
both HIV-positive cases and HIV-negative cases in this study. A predilection of 
HPV 1 for children, plantar warts, and warts of short duration may have excluded 
HPV 1 from our study [37, 40, 43]. The excess of HPV 2 in warts from HIV-
negative cases might be a compensatory phenomenon related to the smaller 
number of HIV-negative patients that harbor HPV 57.  
What was also apparent from these results is the greater median number of 
Betapapillomavirus types in warts from HIV-infected patients and the higher 
proportion of warts with mixed Betapapillomavirus types. This excess of 
Betapapilloma-virus types in HIV-infected patients might be related to 
immunodysfunction (similar to the situation in organ transplant recipients) or due 
to the number of close contacts or lifetime sex partners (as appears to be the case 
for genital HPVs).  
Epidermodysplasia verruciformis–like eruptions have been reported in HIV-
infected individuals [48], although none of the individuals included in this study 
had this clinical phenotype.  
In summary, HIV-infected individuals with warts were more likely to be HLA-
B*44 positive and have the haplotype HLA-B*44, -C*05 than either HIV-infected 
controls or the general population. The potentially protective allele HLA-
DQB1*06 was increased in HIV-positive controls to lesser degree. However, the 
power of the study is too small to draw definite conclusions, and further work is 
necessary to validate our findings. We have also characterized the HPV profile in 
this same group of Caucasoid patients and identified some differences from a 
control population; in particular, our data suggest that HPV 7 may be an important 
pathogen in HIV-infected patients.  
The emergent alleles of interest fit within the context of previous work and 
potentially may involve the interaction of HLA and KIR ligands. 
Immunogenotypic influences are unlikely to compose the entire picture, and other 
factors probably are important in HPV disease during treated HIV infection, such 
as as-yet unelucidated or unquantified immunodysfunction or variations in 
immune adaptivity. These might include thymic generation of naive CD4+ T cells, 
immunosenescence or host phenotypic factors such as CD4+ T-helper cell type 1/2 
polarization, HIV-associated CD4+ T-cell predominant immune decimation and 
dysregulation, regulatory T-cell function, natural killer cells, and/or CD8+ T-cell 
immune responses.  
Regarding the clinical usefulness of our HLA findings, they are consistent with the 
presence of immunosusceptible and immunoprotective genotype(s). This adds 
indirectly to the argument and rationale for prophylactic HPV vaccination in boys, 
as well as for postexposure HPV vaccination in the management of morbidity and 
diminution of mortality due to HPV-related disease in men (and women) in all 
settings. Although prophylactic vaccines may not be therapeutic, vaccination can 
impart cross-reactive immunity to other HPV types [49]. This is most beneficial 
among younger individuals (age, <26 years); MSM; persons at higher risk of 
HPV-related morbidity, such as HIV-infected patients [50], and perhaps those who 
immunogenetically predisposed to HPV infection. Our clinical practice is 
increasingly to recommend HPV vaccination in these settings.  
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Table 1: Study Participant Demographics  
 
Group 
  
HIV+ cases 
compared with  
HIV+ controls  
 
HIV+ cases 
compared with  
NI cases  
 HIV+  
cases 
HIV+ 
controls 
Non-Infected 
cases 
 p=significance 
level 
p=significance 
level 
Number of       
individuals (n) 
 
49 46 42 
 __ __ 
Age years                            
median (IQR) 
 
45   
(41-54) 
49.5   
(44-56) 
41  
(32-52) 
 
p=0.05  p=0.06 
Sex                                   
(% male) 
 
100% 100% 71% 
 
p=1* p<0.0001* 
HIV Infection 
years median 
(IQR) 
 
14  (8-19) 11  (7-20) 
 
__ 
 
 p=0.62 __  
ART years             
median (IQR) 
 
9.0  (5-13) 8.5  (5-12) 
__  
p=0.96 __  
Risk factors for 
HIV (% MSM) 
 
98% 98% 
15% 
 
 
p=1*  p<0.0001* 
Current CD4 T-
cell cells/µl                   
median (IQR) 
 
483   
(343-693) 
544   
(431-683) 
 
__ 
 
p=0.41 __  
CD4 T-cell nadir     
cells/µl                 
median (IQR) 
 
148   
(41-205) 
137   
(48-205) 
 
__ 
 
p=0.86 __ 
Viral load                         
% undetectable           
(<50 copies/ml) 
 
100% 100% 
  
p=1* __  
Wart disease               
years                    
median (IQR) 
4.0 (1.8-9) __ 
 
3.5  (1.4-5) 
 
 
__ p=0.42 
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Figure 1: HLA-B allele count distribution as percentage of individuals in each group 
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Figure 2: HLA-A, HLA-C, HLA-DRB1 and HLA-DQB1 allele count distributions as percentage of individuals in each group 
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Figure 3: Cutaneous warts - HPV type profile  HIV+ cases 
NI cases 
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Figure 4: Genital warts - HPV type profile  
HIV+ cases  
NI cases 
